Compare Natera Inc. Common Stock (NTRA) vs Warner Music Group Corp (WMG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Natera Inc. Common Stock vs Warner Music Group Corp — how do they compare? Natera Inc. Common Stock trades at $394.6 (market cap $57.03B), while Warner Music Group Corp trades at $28.95 (market cap $15.12B). The key difference: Natera Inc. Common Stock is far larger — about 3.8× Warner Music Group Corp's market cap, and Warner Music Group Corp pays a 2.77% dividend while Natera Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Natera Inc. Common Stock for 0 Days and Warner Music Group Corp for 97 Days on average.
| NTRA | WMG | |
|---|---|---|
Market Cap | $57.03B | $15.12B |
Volume | 1,131,157 | 1,464,172 |
Sector | Health | Media |
52-Week High | $425.64 | $34.72 |
52-Week Low | $179.42 | $23.65 |
Typical Hold Time | 0 Days | 97 Days |
Enterprise Value | $56.18B | $19.42B |
Dividend Yield | — | 2.77% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
NTRA trades at $395.66, down 0.53% today but remains near recent highs. The stock shows mixed technical signals with neutral momentum indicators. Fundamentally, the company demonstrates strong revenue growth ($2.31B in 2025, projected $2.7B in 2026) but continues to operate at a net loss (-$208M in 2025). Recent positive developments include FDA Breakthrough Device designation for its multi-cancer detection assay and regulatory approval in Japan for Signatera.
NTRA presents a growth story with significant analyst support (89% buy ratings) but carries execution risks. The stock trades at premium valuations (P/S 20.48) while still unprofitable. Key catalysts include clinical trial progress and international expansion, though investors face risks from ongoing losses and competitive pressures in precision medicine.
Warner Music Group (WMG) trades at $28.91, up 0.91% on the day, with a bullish technical outlook and strong analyst consensus. Recent earnings show revenue growth to $6.71B in 2025, with net income of $365M, while Q3 2026 results are pending. The stock benefits from positive sentiment around AI partnerships and streaming growth, though it faces margin pressure from rising costs.
The investment outlook is positive, supported by a $39.50 analyst price target and institutional buying. Key opportunities include AI-driven content curation and market share gains, but risks involve competitive pressures and execution challenges amid leadership changes. The stock's current valuation at a P/E of 23.12 appears reasonable given growth prospects.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Natera Inc. Common Stock
Natera, Inc. develops and provides cell-free DNA-based genetic testing across women's health, oncology, organ health, and rare disease, with flagship products including Panorama for noninvasive prenatal screening and Signatera for cancer recurrence monitoring.
Read more on NTRA →About Warner Music Group Corp
Warner Music Group is the third largest of the three major global record labels, with Vivendi's Universal Music in first and Sony Music in second. Warner's larger segment, recorded music, consists of iconic labels like Atlantic Records, Warner Records, and Parlophone Records and popular artists such as Ed Sheeran, Cardi B, Dua Lipa, and Blake Shelton. Warner Chappell, the firm's publishing arm, is the home to over 65,000 composers and songwriters with over a million copyrights represented. Warner is controlled by Access Industries, which owns an 84% economic interest and 99% of voting rights.
Read more on WMG →
